EBITDA Summary of UniPharma Co., Ltd.

UniPharma Co., Ltd.'s latest annual EBITDA in 2023 was -16.25 Million TWD , down -1017.88% from previous year.
UniPharma Co., Ltd.'s latest quarterly EBITDA in 2024 Q2 was -6.17 Million TWD , down -16.63% from previous quarter.
UniPharma Co., Ltd. reported an annual EBITDA of -1.6 Million TWD in 2022, up 97.71% from previous year.
UniPharma Co., Ltd. reported an annual EBITDA of -63.52 Million TWD in 2021, down -44.24% from previous year.
UniPharma Co., Ltd. reported a quarterly EBITDA of -6.17 Million TWD for 2024 Q2, down -16.63% from previous quarter.
UniPharma Co., Ltd. reported a quarterly EBITDA of -8.27 Million TWD for 2023 Q3, down -96.1% from previous quarter.

Annual EBITDA Chart of UniPharma Co., Ltd. (2023 - 2019)

Name	EBITDA	EBITDA Difference
Allied Biotech Corporation	204.79 Million TWD	107.937%
GeneFerm Biotechnology Co., Ltd.	231.09 Million TWD	107.034%
Easywell Biomedicals, Inc.	-85.5 Million TWD	80.99%
TTY Biopharm Company Limited	1.52 Billion TWD	101.066%
Synmosa Biopharma Corporation	1 Billion TWD	101.611%
Orient EuroPharma Co., Ltd.	582.93 Million TWD	102.788%
Center Laboratories, Inc.	-175.17 Million TWD	90.721%
Tien Liang BioTech Co., Ltd.	31.04 Million TWD	152.351%
Orient Pharma Co., Ltd.	172.39 Million TWD	109.428%
InnoPharmax Inc.	-62.12 Million TWD	73.835%
Johnson Chemical Pharmaceutical Works Co., Ltd.	126.67 Million TWD	112.831%
Excelsior Biopharma Inc.	-29.36 Million TWD	44.656%
DV Biomed Co., Ltd.	407.64 Million TWD	103.987%
Foresee Pharmaceuticals Co., Ltd.	-912.16 Million TWD	98.218%
Handa Pharmaceuticals, Inc.	802.78 Million TWD	102.025%
Anxo Pharmaceutical Co., Ltd.	131.31 Million TWD	112.378%
Alar Pharmaceuticals Inc.	394.52 Million TWD	104.12%
Winston Medical Supply Co., Ltd.	228.32 Million TWD	107.119%
Mercury Biopharmaceutical Corporation	-39.03 Million TWD	58.359%
Bioray Biotech Co., Ltd	12.13 Million TWD	233.943%
TSH Biopharm Corporation Limited	99.35 Million TWD	116.36%